Australia's most trusted
source of pharma news
Monday, 03 August 2026
Posted 3 August 2026 AM
Eight companies have scored an August PBS listing and more than half of the winners are new drugs.
Among the newcomers is Chiesi’s Elfabrio, an enzyme replacement therapy for Fabry disease, and Servier Laboratories Voranigo, a dual inhibitor of IDH-1 and IDH-2, for the treatment of IDH-mutant astrocytoma or oligodendroglioma.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.